Findings

What do systematic reviews say?

61 questions · 62 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 36 · 58.1%Very low 3 · 4.8%Low 7 · 11.3%Moderate 8 · 12.9%High 8 · 12.9%

Mefloquine vs atovaquone‐proguanil

Anxiety · non‐immune adults and children travelling to or living in malaria‐endemic settings

Mefloquine led to higher anxiety compared with atovaquone‐proguanil; GRADE not reported.

1 finding from 1 review

Mefloquine for preventing malaria during travel to endemic areas 2017 · Cochrane Headline outcomes only
RR 6.12 [1.82, 20.66]
1 study · 976 participants
GRADE not reported

Mefloquine vs atovaquone‐proguanil

Depressed mood · non‐immune adults and children travelling to or living in malaria‐endemic settings

Mefloquine led to higher depressed mood compared with atovaquone‐proguanil; GRADE not reported.

1 finding from 1 review

Mefloquine for preventing malaria during travel to endemic areas 2017 · Cochrane Headline outcomes only
RR 5.78 [1.71, 19.61]
1 study · 976 participants
GRADE not reported

Mefloquine vs atovaquone‐proguanil

Abnormal thoughts or perceptions · non‐immune adults and children travelling to or living in malaria‐endemic settings

Mefloquine showed no clear difference in abnormal thoughts or perceptions compared with atovaquone‐proguanil; GRADE not reported.

1 finding from 1 review

Mefloquine for preventing malaria during travel to endemic areas 2017 · Cochrane Headline outcomes only
RR 1.5 [0.3, 7.42]
3 studies · 2433 participants
GRADE not reported

Mefloquine vs atovaquone‐proguanil

Nausea · non‐immune adults and children travelling to or living in malaria‐endemic settings

Mefloquine led to higher nausea compared with atovaquone‐proguanil; GRADE not reported.

1 finding from 1 review

Mefloquine for preventing malaria during travel to endemic areas 2017 · Cochrane Headline outcomes only
RR 2.72 [1.52, 4.86]
1 study · 976 participants
GRADE not reported

Mefloquine plus cotrimoxazole vs cotrimoxazole

Maternal parasitaemia (at delivery) · HIV‐infected pregnant women

Mefloquine plus cotrimoxazole probably leads to lower maternal peripheral parasitaemia at delivery (PCR) compared with cotrimoxazole (moderate certainty).

1 finding from 1 review

Mefloquine for preventing malaria in pregnant women 2018 · Cochrane Headline outcomes only
RR 0.52 [0.3, 0.93]
2 studies · 989 participants
Moderate

Mefloquine plus cotrimoxazole vs cotrimoxazole

Placental malaria · HIV‐infected pregnant women

Mefloquine plus cotrimoxazole probably leads to lower placental malaria (PCR) compared with cotrimoxazole (moderate certainty).

1 finding from 1 review

Mefloquine for preventing malaria in pregnant women 2018 · Cochrane Headline outcomes only
RR 0.28 [0.14, 0.57]
2 studies · 977 participants
Moderate

Mefloquine plus cotrimoxazole vs cotrimoxazole

Maternal anaemia at delivery · HIV‐infected pregnant women

Mefloquine plus cotrimoxazole showed no clear difference in maternal anaemia at delivery compared with cotrimoxazole (moderate certainty).

1 finding from 1 review

Mefloquine for preventing malaria in pregnant women 2018 · Cochrane Headline outcomes only
RR 0.94 [0.73, 1.2]
2 studies · 1197 participants
Moderate

Mefloquine plus cotrimoxazole vs cotrimoxazole

Low birthweight · HIV‐infected pregnant women

Mefloquine plus cotrimoxazole showed no clear difference in low birth weight compared with cotrimoxazole (moderate certainty).

1 finding from 1 review

Mefloquine for preventing malaria in pregnant women 2018 · Cochrane Headline outcomes only
RR 1.2 [0.89, 1.6]
2 studies · 1220 participants
Moderate

Mefloquine plus cotrimoxazole vs cotrimoxazole

Spontaneous abortions and stillbirths · HIV‐infected pregnant women

It is very uncertain whether mefloquine plus cotrimoxazole changes spontaneous abortions and stillbirths compared with cotrimoxazole (very low certainty).

1 finding from 1 review

Mefloquine for preventing malaria in pregnant women 2018 · Cochrane Headline outcomes only
RR 1.12 [0.42, 2.98]
2 studies · 1347 participants
Very low

Mefloquine plus cotrimoxazole vs cotrimoxazole

Vomiting · HIV‐infected pregnant women

Mefloquine plus cotrimoxazole leads to higher AEs: vomiting compared with cotrimoxazole (high certainty).

1 finding from 1 review

Mefloquine for preventing malaria in pregnant women 2018 · Cochrane Headline outcomes only
RR 7.95 [4.79, 13.18]
1 study · 1055 participants
High

Mefloquine plus cotrimoxazole vs cotrimoxazole

Dizziness · HIV‐infected pregnant women

Mefloquine plus cotrimoxazole leads to higher AEs: dizziness compared with cotrimoxazole (high certainty).

1 finding from 1 review

Mefloquine for preventing malaria in pregnant women 2018 · Cochrane Headline outcomes only
RR 3.94 [2.85, 5.46]
1 study · 1055 participants
High

Mefloquine plus cotrimoxazole vs cotrimoxazole

Clinical malaria episodes during pregnancy · HIV‐infected pregnant women

Mefloquine plus cotrimoxazole showed no clear difference in clinical malaria episodes during pregnancy compared with cotrimoxazole (high certainty).

1 finding from 1 review

Mefloquine for preventing malaria in pregnant women 2018 · Cochrane Headline outcomes only
IRR 0.76 [0.33, 1.76]
1 study · 1 participants
High

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.37 [0.13, 1.05]
1 study · 1117 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 1.8 [0.9, 3.57]
1 study · 1037 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) probably leads to lower total failure: day 28 (unadjusted) compared with mefloquine plus artesunate (MQ + AS) (moderate certainty).

2 findings from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.36 [0.17, 0.78]
1 study · 1120 participants
Moderate
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.84 [0.54, 1.31]
1 study · 1059 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 1 [0.25, 3.97]
1 study · 1271 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 7.48 [0.99, 56.45]
1 study · 1271 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 9.49 [0.55, 162.64]
1 study · 1271 participants
Very low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 3.49 [0.43, 28.29]
1 study · 1271 participants
Very low

Atovaquone‐proguanil vs mefloquine plus artesunate (MQ + AS)

Total failure: day 42 (PCR‐adjusted) · children and adults

Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artesunate‐mefloquine (high certainty).

1 finding from 1 review

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria 2021 · Cochrane Headline outcomes only
RR 1.15 [0.57, 2.34]
2 studies · 1168 participants
High